The C1N2 monoclonal antibody specifically binds to the Toll-like receptor 6 (TLR6), which is also known as CD286. CD286 belongs to the mammalian toll-like family of pattern recognition receptors (TLR) that participate in inducing innate immune responses to microbial pathogens. CD286 is a type I transmembrane glycoprotein comprised of an extracellular domain with a large number of leucinerich repeats (LRRs) and a cytoplasmic region with a signaling Toll/Interleukin-1 Receptor (TIR) domain. TLR6 is differentially expressed on the surface and intracellular compartments, including endolysosomes, of pre-B cells as well as immature or mature B cells. It is likewise expressed by monocytes, macrophages, or plasmacytoid, CD4+, or CD8+ dendritic cells. In association with TLR2 (CD282), CD286 recognizes microbial diacylated lipopeptides, lipoteichoic acid, and zymosan. The CD282/CD286 (TLR2/TLR60 heterodimer then transduces signaling responses leading to the production of proinflammatory cytokines by responding cells.
The antibody was conjugated to an oligonucleotide that contains an antibody clone-specific barcode (ABC) flanked by a poly-A tail on the 3' end and a PCR handle (PCR primer binding site) on the 5' end. The ABC for this antibody was designed to be used with other BD AbSeq oligonucleotides conjugated to other antibodies. All AbSeq ABC sequences were selected in silico to be unique from human and mouse genomes, have low predicted secondary structure, and have high Hamming distance within the BD AbSeq portfolio, to allow for sequencing error correction and unique mapping. The poly-A tail of the oligonucleotide allows the ABC to be captured by the BD Rhapsody™ system. The 5' PCR handle allows for efficient sequencing library generation for Illumina sequencing platforms.
NOTE: The BD Rhapsody Single-Cell Analysis System must be used with the BD Rhapsody Express Instrument.